159 related articles for article (PubMed ID: 28968497)
1. From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging.
Caillé F; Cacheux F; Peyronneau MA; Jego B; Jaumain E; Pottier G; Ullmer C; Grether U; Winkeler A; Dollé F; Damont A; Kuhnast B
Mol Pharm; 2017 Nov; 14(11):4064-4078. PubMed ID: 28968497
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2.
Slavik R; Müller Herde A; Haider A; Krämer SD; Weber M; Schibli R; Ametamey SM; Mu L
J Neurochem; 2016 Sep; 138(6):874-86. PubMed ID: 27385045
[TBL] [Abstract][Full Text] [Related]
3. Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging.
Modemann DJ; Mahardhika AB; Yamoune S; Kreyenschmidt AK; Maaß F; Kremers S; Breunig C; Sahlmann CO; Bucerius J; Stalke D; Wiltfang J; Bouter Y; Müller CE; Bouter C; Meller B
Eur J Med Chem; 2022 Mar; 232():114138. PubMed ID: 35193075
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Structure-Activity Relationships, Radiofluorination, and Biological Evaluation of [
Teodoro R; Gündel D; Deuther-Conrad W; Kazimir A; Toussaint M; Wenzel B; Bormans G; Hey-Hawkins E; Kopka K; Brust P; Moldovan RP
J Med Chem; 2023 Oct; 66(20):13991-14010. PubMed ID: 37816245
[TBL] [Abstract][Full Text] [Related]
5. Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study.
Hassan AHE; Park KT; Kim HJ; Lee HJ; Kwon YH; Hwang JY; Jang CG; Chung JH; Park KD; Lee SJ; Oh SJ; Lee YS
Bioorg Chem; 2020 Jun; 99():103834. PubMed ID: 32334193
[TBL] [Abstract][Full Text] [Related]
6. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease.
Ahmad R; Postnov A; Bormans G; Versijpt J; Vandenbulcke M; Van Laere K
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2219-2227. PubMed ID: 27488857
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of cannabinoid type 2 receptors with [
Pottier G; Gómez-Vallejo V; Padro D; Boisgard R; Dollé F; Llop J; Winkeler A; Martín A
J Cereb Blood Flow Metab; 2017 Mar; 37(3):1163-1178. PubMed ID: 28079433
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design, Optimization, and Development of [
Gündel D; Deuther-Conrad W; Ueberham L; Kaur S; Otikova E; Teodoro R; Toussaint M; Lai TH; Clauß O; Scheunemann M; Bormans G; Bachmann M; Kopka K; Brust P; Moldovan RP
J Med Chem; 2022 Jul; 65(13):9034-9049. PubMed ID: 35771668
[TBL] [Abstract][Full Text] [Related]
10. Development of [
Teodoro R; Gündel D; Deuther-Conrad W; Ueberham L; Toussaint M; Bormans G; Brust P; Moldovan RP
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360817
[TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors.
Haider A; Kretz J; Gobbi L; Ahmed H; Atz K; Bürkler M; Bartelmus C; Fingerle J; Guba W; Ullmer C; Honer M; Knuesel I; Weber M; Brink A; Herde AM; Keller C; Schibli R; Mu L; Grether U; Ametamey SM
J Med Chem; 2019 Dec; 62(24):11165-11181. PubMed ID: 31751140
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.
Slavik R; Herde AM; Bieri D; Weber M; Schibli R; Krämer SD; Ametamey SM; Mu L
Eur J Med Chem; 2015 Mar; 92():554-64. PubMed ID: 25599952
[TBL] [Abstract][Full Text] [Related]
13. Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor.
Moldovan RP; Teodoro R; Gao Y; Deuther-Conrad W; Kranz M; Wang Y; Kuwabara H; Nakano M; Valentine H; Fischer S; Pomper MG; Wong DF; Dannals RF; Brust P; Horti AG
J Med Chem; 2016 Sep; 59(17):7840-55. PubMed ID: 27500461
[TBL] [Abstract][Full Text] [Related]
14. Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors.
Haider A; Gobbi L; Kretz J; Ullmer C; Brink A; Honer M; Woltering TJ; Muri D; Iding H; Bürkler M; Binder M; Bartelmus C; Knuesel I; Pacher P; Herde AM; Spinelli F; Ahmed H; Atz K; Keller C; Weber M; Schibli R; Mu L; Grether U; Ametamey SM
J Med Chem; 2020 Sep; 63(18):10287-10306. PubMed ID: 32787079
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor.
Mu L; Bieri D; Slavik R; Drandarov K; Müller A; Cermak S; Weber M; Schibli R; Krämer SD; Ametamey SM
J Neurochem; 2013 Sep; 126(5):616-24. PubMed ID: 23795580
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging.
Evens N; Muccioli GG; Houbrechts N; Lambert DM; Verbruggen AM; Van Laere K; Bormans GM
Nucl Med Biol; 2009 May; 36(4):455-65. PubMed ID: 19423014
[TBL] [Abstract][Full Text] [Related]
17. In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI.
Ni R; Müller Herde A; Haider A; Keller C; Louloudis G; Vaas M; Schibli R; Ametamey SM; Klohs J; Mu L
Mol Imaging Biol; 2022 Oct; 24(5):700-709. PubMed ID: 34642898
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor.
Turkman N; Shavrin A; Paolillo V; Yeh HH; Flores L; Soghomonian S; Rabinovich B; Volgin A; Gelovani J; Alauddin M
Nucl Med Biol; 2012 May; 39(4):593-600. PubMed ID: 22226022
[TBL] [Abstract][Full Text] [Related]
19. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system.
Ni R; Mu L; Ametamey S
Acta Pharmacol Sin; 2019 Mar; 40(3):351-357. PubMed ID: 29921889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
